Marianne Stulich

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Suppression of telomerase activity in tumor cells has been considered as a new anticancer strategy. Here, we present chimeric oligonucleotides (chimeric ODNs) as a new type of telomerase inhibitor that contains differently modified oligomers to address two different sites of telomerase: the RNA template and a suggested protein motif. We have shown(More)
A new generic drug of atenolol, Atenolol (A), (Fahlberg-List Magdeburg, Germany) was studied in comparison with standard preparation (S) in their pharmacokinetic behaviour in 12 patients under steady state conditions. The concentration-time-profile of both preparations was nearly identical. The half time of elimination was calculated for A at 6.5 h and for(More)
  • 1